Lancet Infectious Diseases

(The median citation count of Lancet Infectious Diseases is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)
Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study1264
A minimal common outcome measure set for COVID-19 clinical research1154
A clinical case definition of post-COVID-19 condition by a Delphi consensus1112
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial1050
Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study938
Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics931
Global impact of the first year of COVID-19 vaccination: a mathematical modelling study897
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial891
Real estimates of mortality following COVID-19 infection856
Clinical features and management of human monkeypox: a retrospective observational study in the UK757
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study723
Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study648
The value of antimicrobial peptides in the age of resistance637
Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study628
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study579
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance568
COVID-19 and multisystem inflammatory syndrome in children and adolescents565
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study558
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study535
Genomic evidence for reinfection with SARS-CoV-2: a case study512
Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study474
Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study463
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2461
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, mult445
Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study437
COVID-19 and medical education416
A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation413
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical 404
Stigma during the COVID-19 pandemic382
Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series355
The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries350
Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study350
Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study343
The many estimates of the COVID-19 case fatality rate341
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 335
Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic surveillance study334
Risk of COVID-19 in health-care workers in Denmark: an observational cohort study332
Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis316
The COVID-19 infodemic305
Exaggerated risk of transmission of COVID-19 by fomites302
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison301
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial301
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression300
Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study284
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial257
Serology testing in the COVID-19 pandemic response250
Pooling of samples for testing for SARS-CoV-2 in asymptomatic people249
Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study248
Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–15: an analysis of pharmaceutical sales data244
Smell and taste dysfunction in patients with COVID-19242
Long-term consequences of COVID-19: research needs239
Scaling up COVID-19 rapid antigen tests: promises and challenges239
Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study236
SARS-CoV-2 infection and transmission in educational settings: a prospective, cross-sectional analysis of infection clusters and outbreaks in England235
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised232
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial230
Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT228
Changes in colistin resistance and mcr-1 abundance in Escherichia coli of animal and human origins following the ban of colistin-positive additives in China: an epidemiological comparative study223
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial223
The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis217
Willingness to vaccinate against COVID-19 in Australia216
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-cont212
Connecting clusters of COVID-19: an epidemiological and serological investigation210
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical tri203
COVID-19 in health-care workers in three hospitals in the south of the Netherlands: a cross-sectional study202
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study201
The global incidence and diagnosis of fungal keratitis199
Monitoring approaches for health-care workers during the COVID-19 pandemic194
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden194
Intention to vaccinate against COVID-19 in Australia192
Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study191
Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis191
The indirect impact of COVID-19 on women190
Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and 185
Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis185
Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design184
Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study181
The important role of serology for COVID-19 control178
ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5177
Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial175
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial173
What reinfections mean for COVID-19168
SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study167
Global shortage of personal protective equipment167
Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis165
Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wav165
Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis163
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape162
SeroTracker: a global SARS-CoV-2 seroprevalence dashboard161
SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity161
Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding160
Baricitinib for COVID-19: a suitable treatment?160
Utility of hyposmia and hypogeusia for the diagnosis of COVID-19156
Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study155
Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study154
Individual quarantine versus active monitoring of contacts for the mitigation of COVID-19: a modelling study151
Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review150
Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: a geospatial modelling analysis149
Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis146
Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study145
Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study142
Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies142
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial141
Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial140
Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US138
COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England136
Monkeypox outbreaks outside endemic regions: scientific and social priorities136
Prevention of monkeypox with vaccines: a rapid review134
Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study133
Monoclonal antibody therapies against SARS-CoV-2133
China's successful control of COVID-19132
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial130
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study127
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial126
Concerns and motivations about COVID-19 vaccination125
Bell's palsy and SARS-CoV-2 vaccines125
SARS-CoV-2 and the human-animal interface: outbreaks on mink farms124
Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective obse124
Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB123
Hospitalisation among vaccine breakthrough COVID-19 infections121
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled117
Vaccinology: time to change the paradigm?117
Low risk of SARS-CoV-2 transmission by fomites in real-life conditions117
Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2116
Estimating case fatality rates of COVID-19115
Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and An113
Protective immunity after recovery from SARS-CoV-2 infection113
Tracking the 2022 monkeypox outbreak with epidemiological data in real-time112
Omicron sublineage BQ.1.1 resistance to monoclonal antibodies111
SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study111
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study111
RT-PCR for SARS-CoV-2: quantitative versus qualitative110
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial109
The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation108
Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study108
Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe106
Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2106
New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial105
The urgent need for metallo-β-lactamase inhibitors: an unattended global threat105
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (CO105
Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study104
ChatGPT and antimicrobial advice: the end of the consulting infection doctor?104
Genomic-informed pathogen surveillance in Africa: opportunities and challenges103
Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant101
BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial100
Defining the determinants of vaccine uptake and undervaccination in migrant populations in Europe to improve routine and COVID-19 vaccine uptake: a systematic review100
Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis100
Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure99
Sources of persistent malaria transmission in a setting with effective malaria control in eastern Uganda: a longitudinal, observational cohort study99
100 years of Mycobacterium bovis bacille Calmette-Guérin98
Appropriateness of antibiotic prescriptions in ambulatory care in China: a nationwide descriptive database study97
SARS-CoV-2 shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series96
Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study96
Association of tiered restrictions and a second lockdown with COVID-19 deaths and hospital admissions in England: a modelling study95
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial95
Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland95
Hand hygiene in health care: 20 years of ongoing advances and perspectives92
Global burden and trends of sexually transmitted infections from 1990 to 2019: an observational trend study92
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study91
The world's largest COVID-19 vaccination campaign90
Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial90
The place for remdesivir in COVID-19 treatment89
Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study88
Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM88
Risk predictors of progression to severe disease during the febrile phase of dengue: a systematic review and meta-analysis88
Long COVID in the skin: a registry analysis of COVID-19 dermatological duration87
Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant87
Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant86
Lung fibrosis: an undervalued finding in COVID-19 pathological series85
Hospital-treated infectious diseases and the risk of dementia: a large, multicohort, observational study with a replication cohort85
COVID-19 human challenge studies: ethical issues85
Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.584
The importance of understanding the infectious microenvironment84
Complications and mortality of non-typhoidal salmonella invasive disease: a global systematic review and meta-analysis83
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study83
Viral loads in clinical samples of men with monkeypox virus infection: a French case series82
Review of 2022 WHO guidelines on the control and elimination of schistosomiasis81
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial81
Hydroxychloroquine prophylaxis for COVID-19 contacts in India80
Effect of preventive chemotherapy with praziquantel on schistosomiasis among school-aged children in sub-Saharan Africa: a spatiotemporal modelling study79
Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.379
First detection of SARS-CoV-2 spike protein N501 mutation in Italy in August, 202079
Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.8678
Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation 78
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial77
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study77
The intersection of COVID-19 and mental health77
Age–sex differences in the global burden of lower respiratory infections and risk factors, 1990–2019: results from the Global Burden of Disease Study 201976
Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study75
Measuring the effects of COVID-19-related disruption on dengue transmission in southeast Asia and Latin America: a statistical modelling study75
The scientific and ethical feasibility of immunity passports74
Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial74
Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy s74
Chloroquine or hydroxychloroquine for prophylaxis of COVID-1974
Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study74
Epidemiological and clinical characteristics of patients with monkeypox in the GeoSentinel Network: a cross-sectional study74
Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates: a systematic review and meta-analysis74
Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective 74
Effectiveness of one dose of MVA–BN smallpox vaccine against mpox in England using the case-coverage method: an observational study72
Interferon-γ release assays or tuberculin skin test for detection and management of latent tuberculosis infection: a systematic review and meta-analysis72
Effect of postoperative continuation of antibiotic prophylaxis on the incidence of surgical site infection: a systematic review and meta-analysis71
Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark71
Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study70
Virological characteristics of the SARS-CoV-2 JN.1 variant69
Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controll69
Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac68
SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020–2167
The Johns Hopkins University Center for Systems Science and Engineering COVID-19 Dashboard: data collection process, challenges faced, and lessons learned67
Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study67
Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study66
Case isolation, contact tracing, and physical distancing are pillars of COVID-19 pandemic control, not optional choices66
Antibiotic prescribing in general practice during COVID-1965
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-65
COVID-19 vaccine equity and booster doses65
Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study64
Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak64
Persistence of IgG response to SARS-CoV-263
The Darwin Prospective Melioidosis Study: a 30-year prospective, observational investigation63
Global increases in antibiotic consumption: a concerning trend for WHO targets63
Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant63
CoronaVac induces lower neutralising activity against variants of concern than natural infection63
Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study63
Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccinati63
Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants62
Long COVID: tackling a multifaceted condition requires a multidisciplinary approach62
Viral dynamics in patients with monkeypox infection: a prospective cohort study in Spain61
The origin of SARS-CoV-261
Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study61
Quantifying the global number of tuberculosis survivors: a modelling study61
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial61
Observations of the global epidemiology of COVID-19 from the prepandemic period using web-based surveillance: a cross-sectional analysis60
Hospitalisation associated with SARS-CoV-2 delta variant in Denmark60
Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990–2019: results from the Global Burden of Disease Study 201960
A case of SARS-CoV-2 reinfection in Ecuador59
Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate58
Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies58
Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial58
Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens58
Prevention of host-to-host transmission by SARS-CoV-2 vaccines58
Global incidence and mortality of severe fungal disease57
Associations between phone mobility data and COVID-19 cases57
Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negati57
Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases57
Global COVID-19 vaccine inequity56
Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection56
Why we need a deeper understanding of the pathophysiology of long COVID56
Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial56
Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity56
Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology a55
25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward55